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Primary tumors of the trachea are rare and account for 0.1% of all malignancies \[[@B1]\]. In adults, approximately 90% of the primary tracheal tumors are malignant, whereas in children, the majority of these tumors are benign \[[@B2], [@B3]\]. In a retrospective study by Webb et al. \[[@B4]\], 55.4% of the patients were male and 77.3% of them were smokers. The frequency of this rare disease has been estimated to be 0.1--0.4% of all malignancies, with an annual incidence of 2.6 new cases per million per year \[[@B5]\].

Primary tracheal tumors can arise from the respiratory epithelium, salivary glands and mesenchymal structure of the trachea. Squamous cell carcinoma (SCC) and adenoid cystic carcinoma (ACC) make up about 71.6% of all adult primary tracheal tumors. The remaining portion (28.4%) is widely distributed in a heterogeneous group of malignant tumors \[[@B4]\]. SCC occurs predominantly in men in the sixth and seventh decades, whereas ACC is equally distributed between the sexes and peaks in incidence in the fourth and fifth decades \[[@B6]\]. In contrast to ACC, SCC (the most common type of tracheal tumors) has a more aggressive course. Median survival time ranges from 6 to 14 months, and tumor disappearance is dependent on whether the primary lesion is resected. SCCs spread to the lymph nodes and 10--20% of the patients will have distant metastasis at presentation. For other pathologic variants, the clinical course and natural history are variable. Carcinoids, lymphomas, granular cell tumors and small cell carcinomas have variable prognoses; yet they seem to behave better than SCCs, adenocarcinomas or sarcomas. The majority of the tracheal neoplasms are primary in nature, and other primary sites that can metastasize to the trachea are the lung and esophagus, the latter being the most common. Patients with surgically resectable primary tracheal tumors have a better prognosis than those with tumors that cannot be resected. Preoperative radiation therapy has been attempted in some patients, yet the most compelling evidence for adjuvant radiation therapy comes from postoperative cases \[[@B7]\]. The present study reports a rare case of primary tracheal malignancy treated with surgery and adjuvant radiation therapy. The patient has given his informed consent and the study meets all ethical requirements.

Case Presentation {#sec1_2}
=================

Our 60-year-old diabetic and hypertensive male patient had a 1-month history of cough associated with marked respiratory distress and occasional dyspnea in the right lateral lying position. The patient consulted a chest physician and underwent bronchoscopy, which showed a polypoid growth in the trachea extending to the larynx (fig. [1](#F1){ref-type="fig"}). A computed tomography (CT) scan revealed irregular soft tissue thickening in the region of the trachea extending up to the adjacent larynx with no soft tissue calcification, and there was no definite lymphadenopathy in the cervical region and no involvement of the underlying bone. A repeat CT scan of the neck (fig. [2](#F2){ref-type="fig"}) showed evidence of an ill-defined, irregular, nodular, infiltrating soft tissue growth arising from the posterior tracheal wall, bridging the lumen and reaching up to the anterior wall, with an infiltration of about 2.2 × 1.8 cm. The location was opposite the C7-D1 level involving the 5th or 6th tracheal ring, approximately 7 cm proximal to the carina with no significant evidence of cervical and mediastinal lymphadenopathy.

Excision of the tracheal growth through a cervical transverse incision was performed, and a tracheostomy tube was inserted. Histopathology revealed an atypical carcinoid with lymphatic invasion. Immunocytochemistry was positive for pancytokeratin and negative for chromogranin-A. The case was finally diagnosed as adenocarcinoma of the trachea.

Soon after surgery, the cough subsided and the patient attended Square Hospital, Dhaka, Bangladesh, for postoperative irradiation. The prescribed photon radiation dose was 56 Gy in 28 fractions. Ninety-five percent of the planning target volume (PTV) covered 97.3% of the prescribed dose. The minimum and maximum dose received by the PTV was 50.05 and 63.68 Gy, respectively. The dose distribution is illustrated below (fig. [3](#F3){ref-type="fig"}). Three multileaf collimator fields (left anterior oblique, right anterior oblique and posterior) were used for three-dimensional conformal radiation therapy (3DCRT). The radiation dose distribution within the PTV is shown by color wash (fig. [3](#F3){ref-type="fig"}). Complete response was documented, and the patient is still alive without any evidence of disease during 30 months of follow-up.
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Primary malignant tumors of the trachea are uncommon, and therefore limited data supporting a standard management are available. The vast majority of the primary tracheal tumors in adults are malignant and most of them usually diagnosed at a later stage, which is due to a delayed presentation of specific symptoms like cough, dyspnea and hemoptysis.

It is clear that patients who can be resected have a better prognosis than those who cannot, prompting the recommendation of surgical resection for most primary tracheal tumors. All resected patients need postsurgical irradiation, regardless of tumor burden, margin status, histology or nodal status \[[@B7]\].

Grillo and Mathisen \[[@B8]\] experienced a median survival of 34 months in SCC and 118 months in ACC patients who underwent a combined modality like surgery and radiation therapy. Similarly, Chow et al. \[[@B9]\] attained a 61-month median survival using a combined surgery and radiation therapy in their study. Regnard et al. \[[@B10]\] showed that 73% of the patients with a 5-year survival underwent radiation therapy postoperatively.

The role of external beam radiation therapy as an adjuvant to surgical resection is better established. Grillo and Mathisen \[[@B8]\] advocated maximal (4,500--6,500 cGy) radiation therapy after SCC and ACC resection because of the close margins necessary for resection and the high likelihood of local recurrence \[[@B5]\]. Modern CT-based 3DCRT or intensity-modulated radiation therapy theoretically allows higher and safer doses delivered to the trachea. For postoperative cases, experiences seem to indicate that a dose of 50--60 Gy should be used. All patients with this tumor in the postoperative or definitive setting should be treated with the 3DCRT technique. An intraluminal boost technique after external beam radiation therapy may decrease the risk of late side effects \[[@B7]\].

There are many studies showing the benefit of postoperative irradiation therapy in primary tracheal malignancies such as SCCs and ACCs. However, little experience has been shared in the case of primary adenocarcinomas of the trachea, the tumor type described in our report. The prognosis of patients with malignant tumors of the trachea remains gloomy, and long-term median survival of tracheal adenocarcinoma patients undergoing combined modalities is unknown to us. Primary adenocarcinoma of the trachea needs to be diagnosed at an early stage, and combined multimodal approaches may be explored to attain an extended median survival.
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